Trial · NCT00466960
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Progression | Treatment (Colony Stimulating Factor and Chemotherapy) | 4.07 | 95% Confidence Interval 2.74 to 6.71 | months | |
| Response Rate | Treatment (Colony Stimulating Factor and Chemotherapy) | 15 | Participants | ||
| Correlation Between Circulating Monocytes and Time to Progression | Treatment (Colony Stimulating Factor and Chemotherapy) | CR | 20.75 | Inter-Quartile Range 10.98 to 24.93 | percentage of CD45+ in PBSC |
| Correlation Between Circulating Monocytes and Time to Progression | Treatment (Colony Stimulating Factor and Chemotherapy) | PR+NR+SD | 12.75 | Inter-Quartile Range 11.24 to 30.1 | percentage of CD45+ in PBSC |
| Correlation Between Circulating Dendritic Cell Count and Maturation State With Clinical Response and Response Duration | Treatment (Colony Stimulating Factor and Chemotherapy) | mDC in CR | 1.543 | Inter-Quartile Range 1.075 to 3.504 | % of CD45+PBMC |
| Correlation Between Circulating Dendritic Cell Count and Maturation State With Clinical Response and Response Duration | Treatment (Colony Stimulating Factor and Chemotherapy) | mDC in PR+NR+SD | 1.996 | Inter-Quartile Range 1.232 to 2.42 | % of CD45+PBMC |
| Correlation Between Circulating Dendritic Cell Count and Maturation State With Clinical Response and Response Duration | Treatment (Colony Stimulating Factor and Chemotherapy) | pDC in CR | 0.2465 | Inter-Quartile Range 0.1924 to 0.3362 | % of CD45+PBMC |
| Correlation Between Circulating Dendritic Cell Count and Maturation State With Clinical Response and Response Duration | Treatment (Colony Stimulating Factor and Chemotherapy) | pDC in PR+NR+SD | 0.3743 | Inter-Quartile Range 0.2311 to 0.5067 | % of CD45+PBMC |
| Precursor Frequency of Circulating Activated T Lymphocytes Against Common Ovarian Cancer Tumor Associated Antigens to Measure the Development of Immunity to Anti-tumor Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | IGF1R-p1196-1210 | 0.5056 | 95% Confidence Interval -0.03429 to 0.8171 | Pearson correlation |
| Precursor Frequency of Circulating Activated T Lymphocytes Against Common Ovarian Cancer Tumor Associated Antigens to Measure the Development of Immunity to Anti-tumor Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | IGF1R-p1242-1256 | 0.8496 | 95% Confidence Interval 0.5807 to 0.9513 | Pearson correlation |
| Precursor Frequency of Circulating Activated T Lymphocytes Against Common Ovarian Cancer Tumor Associated Antigens to Measure the Development of Immunity to Anti-tumor Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | IGF1R-p1332-1346 | 0.8269 | 95% Confidence Interval 0.5279 to 0.9435 | Pearson correlation |
| Precursor Frequency of Circulating Activated T Lymphocytes Against Common Ovarian Cancer Tumor Associated Antigens to Measure the Development of Immunity to Anti-tumor Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | IGFBP2 | 0.3676 | 95% Confidence Interval -0.2982 to 0.7927 | Pearson correlation |
| Precursor Frequency of Circulating Activated T Lymphocytes Against Common Ovarian Cancer Tumor Associated Antigens to Measure the Development of Immunity to Anti-tumor Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | p53 | -0.02268 | 95% Confidence Interval -0.5667 to 0.5351 | Pearson correlation |
| Precursor Frequency of Circulating Activated T Lymphocytes Against Common Ovarian Cancer Tumor Associated Antigens to Measure the Development of Immunity to Anti-tumor Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | PRAME | -0.0817 | 95% Confidence Interval -0.5869 to 0.4693 | Pearson correlation |
| Precursor Frequency of Circulating T Lymphocytes Activated Against Foreign Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | PHA | -0.08759 | 95% Confidence Interval -0.5908 to 0.4647 | Pearson correlation |
| Precursor Frequency of Circulating T Lymphocytes Activated Against Foreign Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | CEF | -0.1818 | 95% Confidence Interval -0.6498 to 0.3862 | Pearson correlation |
| Precursor Frequency of Circulating T Lymphocytes Activated Against Foreign Antigens | Treatment (Colony Stimulating Factor and Chemotherapy) | tetanus toxoid | -0.1071 | 95% Confidence Interval -0.6035 to 0.4491 | Pearson correlation |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00466960/results